Blueprint Medicines Corporation Statistics
Share Statistics
Blueprint Medicines Corporation has 63.53M shares outstanding. The number of shares has increased by 3.75% in one year.
| Shares Outstanding | 63.53M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.28% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 62.27M |
| Failed to Deliver (FTD) Shares | 140 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 4.53M, so 7.13% of the outstanding shares have been sold short.
| Short Interest | 4.53M |
| Short % of Shares Out | 7.13% |
| Short % of Float | 7.36% |
| Short Ratio (days to cover) | 7.35 |
Valuation Ratios
The PE ratio is -11.02 and the forward PE ratio is -102.79.
| PE Ratio | -11.02 |
| Forward PE | -102.79 |
| PS Ratio | 22.4 |
| Forward PS | 6.8 |
| PB Ratio | 42.77 |
| P/FCF Ratio | -12.33 |
| PEG Ratio | n/a |
Enterprise Valuation
Blueprint Medicines Corporation has an Enterprise Value (EV) of 6.29B.
| EV / Earnings | -12.4 |
| EV / Sales | 25.22 |
| EV / EBITDA | -13.37 |
| EV / EBIT | -12.93 |
| EV / FCF | -13.89 |
Financial Position
The company has a current ratio of 3.76, with a Debt / Equity ratio of 5.21.
| Current Ratio | 3.76 |
| Quick Ratio | 3.66 |
| Debt / Equity | 5.21 |
| Total Debt / Capitalization | 83.9 |
| Cash Flow / Debt | -0.64 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -3.88% and return on capital (ROIC) is -53.85%.
| Return on Equity (ROE) | -3.88% |
| Return on Assets (ROA) | -0.48% |
| Return on Capital (ROIC) | -53.85% |
| Revenue Per Employee | 390.88K |
| Profits Per Employee | -794.65K |
| Employee Count | 638 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 0.6 |
Taxes
| Income Tax | 968.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 27.33% in the last 52 weeks. The beta is 0.59, so Blueprint Medicines Corporation's price volatility has been higher than the market average.
| Beta | 0.59 |
| 52-Week Price Change | 27.33% |
| 50-Day Moving Average | 93.83 |
| 200-Day Moving Average | 96.82 |
| Relative Strength Index (RSI) | 63.82 |
| Average Volume (20 Days) | 685.74K |
Income Statement
In the last 12 months, Blueprint Medicines Corporation had revenue of 249.38M and earned -506.98M in profits. Earnings per share was -8.37.
| Revenue | 249.38M |
| Gross Profit | 236.58M |
| Operating Income | -486.28M |
| Net Income | -506.98M |
| EBITDA | -470.36M |
| EBIT | -486.28M |
| Earnings Per Share (EPS) | -8.37 |
Balance Sheet
The company has 71.29M in cash and 774.12M in debt, giving a net cash position of -702.84M.
| Cash & Cash Equivalents | 71.29M |
| Total Debt | 774.12M |
| Net Cash | -702.84M |
| Retained Earnings | -2.34B |
| Total Assets | 1.20B |
| Working Capital | 597.19M |
Cash Flow
In the last 12 months, operating cash flow was -436.85M and capital expenditures -16.06M, giving a free cash flow of -452.91M.
| Operating Cash Flow | -436.85M |
| Capital Expenditures | -16.06M |
| Free Cash Flow | -452.91M |
| FCF Per Share | -7.48 |
Margins
Gross margin is 94.87%, with operating and profit margins of -194.99% and -203.3%.
| Gross Margin | 94.87% |
| Operating Margin | -194.99% |
| Pretax Margin | -202.91% |
| Profit Margin | -203.3% |
| EBITDA Margin | -188.61% |
| EBIT Margin | -194.99% |
| FCF Margin | -181.61% |
Dividends & Yields
BPMC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -8.16% |
| FCF Yield | -6.95% |
Analyst Forecast
The average price target for BPMC is $125, which is 21.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $125 |
| Price Target Difference | 21.9% |
| Analyst Consensus | Buy |
| Analyst Count | 18 |
Scores
| Altman Z-Score | 1.36 |
| Piotroski F-Score | 2 |